| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[7-[2-[3-(dimethylamino)-1-azetidinyl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-4-quinazolinyl]-2,7-diazaspiro[3.5]non-2-yl]- | [CAS]
2241720-04-5 | [Synonyms]
KRAS G12C inhibitor 37
2-Propen-1-one, 1-[7-[2-[3-(dimethylamino)-1-azetidinyl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-4-quinazolinyl]-2,7-diazaspiro[3.5]non-2-yl]- | [Molecular Formula]
C35H39F3N8O2 | [MOL File]
2241720-04-5.mol | [Molecular Weight]
660.73 |
| Hazard Information | Back Directory | [Uses]
KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65)[1]. | [References]
[1] Quinazoline compound. Patent WO2018143315A1. |
|
|